Published in AAPS J on January 25, 2008
Detection of pharmacovigilance-related adverse events using electronic health records and automated methods. Clin Pharmacol Ther (2012) 1.29
A secure distributed logistic regression protocol for the detection of rare adverse drug events. J Am Med Inform Assoc (2012) 1.09
Nutrition therapy cost analysis in the US: pre-mixed multi-chamber bag vs compounded parenteral nutrition. Appl Health Econ Health Policy (2011) 1.04
Postmarketing surveillance for "modified-risk" tobacco products. Nicotine Tob Res (2011) 0.88
From Pharmacovigilance to Clinical Care Optimization. Big Data (2014) 0.78
A comparison of active surveillance programs including a spontaneous reporting model for phamacovigilance of adverse drug events in a hospital. Korean J Intern Med (2012) 0.75
Detection of dechallenge in spontaneous reporting systems: a comparison of Bayes methods. Indian J Pharmacol (2014) 0.75
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest (2006) 8.43
Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry (2006) 7.60
National surveillance of emergency department visits for outpatient adverse drug events. JAMA (2006) 6.24
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf (2002) 4.15
Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med (1991) 2.40
Drug-induced liver injury network (DILIN). Hepatology (2004) 1.64
Use of health care databases in pharmacoepidemiology. Basic Clin Pharmacol Toxicol (2006) 1.49
Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf (2003) 1.39
Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf (2005) 1.08
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2007) 3.20
Estimates of acetaminophen (Paracetomal)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf (2006) 3.06
Sodium phosphate tablets and acute phosphate nephropathy. Am J Gastroenterol (2009) 2.80
Lamotrigine and aseptic meningitis. Neurology (2012) 2.70
Surveillance of medical device-related hazards and adverse events in hospitalized patients. JAMA (2004) 2.16
Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg (2009) 2.00
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr (2009) 1.14
Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Hepatology (2009) 1.12
Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: a meta-analysis. J Child Adolesc Psychopharmacol (2006) 1.11
Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf (2009) 1.10
Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol (2011) 0.97
Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage (2010) 0.97
Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med (2007) 0.96
Alosetron: ischemic colitis and serious complications of constipation. Am J Gastroenterol (2006) 0.94
An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Pharmacoepidemiol Drug Saf (2008) 0.81
Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA). Dermatol Ther (2009) 0.79
An observational study of cholecystectomy in patients receiving tegaserod. Drug Saf (2007) 0.78
Patient understanding of drug risks: an evaluation of medication guide assessments. Pharmacoepidemiol Drug Saf (2015) 0.78
Building shared experience to advance practical application of pathway-based toxicology: liver toxicity mode-of-action. ALTEX (2014) 0.78
Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America. Am J Gastroenterol (2003) 0.77
Spontaneous reports of seizure in association with leuprolide (lupron depot), goserelin (zoladex implant), and naferelin (synarel nasal spray). Obstet Gynecol (2013) 0.75
Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood. J Child Adolesc Psychopharmacol (2007) 0.75
U.S. Food and drug administration analysis of strokes associated with raloxifene. Obstet Gynecol (2007) 0.75